We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We all have our own investment strategies. I base my investment decisions on known industry / sector specific data / deals / M&A / licencing etc which form the bulk of my due diligence research from RNS’, industry titles and pharma websites. In a nutshell, PYC work in a sector where hundreds of millions and often billions are paid. The current PYC Mcap is tiny as is the share price. X 10 is £27 million. i.e. Peanuts. Let’s wait and see whether PYC make 20p a share or not in the next 18 months. I think they will…
Good luck, Brighty
And just for clarity are you now claiming to have sold out at 3p despite advising people to "buy on the dips"?
Hahahahahahha
You posted that you were holding over 1% of the company at an average of 5p.
Like I said, get help.
Hahahahahahahahah Belter.
Oh please, you've lost a packet here. Get help, seriously.
Swings and roundabouts on aim as you know... What about the ones I bought at 0.96, up to 3p? shame you didnt listen to those, could have had a nice little earner.. Im comfortable with my holding here as confident where its heading, simple as that ! Ps you are a wally.
Shame you didn't listen from 7p down Stephen, would have saved yourself a packet mate. Embarrassing how you've continued to double down while calling me a wally eh.
Share4.. zzzzzzz, embarrassing !
Sigilon has nothing to do with PYC.
A new COO = more expenses
"Contract awards that PYC will be winning" = Jam tomorrow
The rest of what you post is unrelated to PYC
This is all just hot air.
Any actual numbers? Do you even know the cash it has and how long it's likely to last? (hint: don't use Laura's workings)
Quite the contrary Share4. 20p is a real possibility over the next 12-18 months, if not much sooner. It's called due diligence. On June 29, Eli Lilly announced it planned to acquire Sigilon, a small bio for $34.6 million. Sigilon’s stock jumped over 600%. In addition, check out the following information, below, to see why PYC is looking attractive from an investment perspective:
* Dr Peter Sargent joining PYC as Chief Operating Officer. He held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), Among his earlier roles, Dr Sargent was Head of Business Development for the UK's National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK.
Then factor in the contract awards that PYC will be winning, guided by Dr Sargent, our miniscule current Mcap of £2.5 million, our tiny share price of 2p ish. When you research the sector, like I do, you will see that PYC is in the right sector at the right time, with big pharmaceutical co’s snapping up smaller rivals for eye watering amounts. Eli Lilly’s Sigilon, deal for $34.6 million is just the tip of the iceberg. See below recent transactions in our space:
* GSK Buys Affinivax for $ 2.10B
* AstraZeneca Purchases CinCor Pharma Inc. in $1.8 Billion Acquisition
* Sun Pharmaceutical Industries Acquires Concert Pharma for $576M
* Envision Pharma Group Acquires OKRA.ai
* GSK Acquires Sierra Oncology in 1 Billion+ deal.
* Moderna to Buy Japanese Firm OriCiro in Its First-Ever Acquisition
* Amgen’s $27.8 Billion Acquisition of Horizon Therapeutics
* Pfizer Buys Global Blood Therapeutics for $5.4B
* Pfizer Acquires ReViral for $525M
* Pfizer Acquires Biohaven Pharmaceutical for $11.6 Billion in Cash
* Sandoz Acquires Drug Delivery Device Company to Boost Pipeline
* Thermo Fisher Acquires PeproTech for $1.85 Billion to Boost Gene Therapy Market
* Pfizer to Acquire Arena for £6.7 Billion to Boost Chronic Disease Management
* Novo Nordisk Enters Pharma Acquisition Deal For RNAi Therapies
Plus, AZ earlier this year paid 1 billion for KYM Bio & also paid $2 Billion to partner Quell Therapeutics. There’s also Lilly’s deal for Versanis for $1.925 billion, SOBiovitrum’s CTI Bio deal for $1.7 billion, Astellas buy out of Iveric Bio for $5.9bn & GSK's £1.6Billion Bellus deal and finally on June 26, Shionogi announced its plans to acquire Qpex Bio for $100 million upfront, with potential for additional payments. These and other billion pound deals for bio minnows are becoming the norm in our sector. This makes being a PYC investor even more compelling. You only have to peruse the recent JP Morgan research note re R&D licencing deals in the pharma sector to see that PYC shareholders could be in for a big pay day in due course. 20p is just for starters. It equates to a Mcap of approx. £27 Million. That’s peanuts in our sector as the above resea
It's embarrassing that posters on this board think it's acceptable to imply they've been tipped off about imminent news and make claims that the price is going to go up 10x with no actual explanation as to why.
A red flag for any investor reading here.
That would be amazing brigty
Porky
With all due respect I and others don't care what you think
Grabbed a few before went nt. 2.8p to 1.8p in a few days, worth a top up imo
Nt to buy
Porky, thought you'd said the MCAP was worth more than 1p.
@Laura
Appreciate you are a fan but don't try and catch a falling knife
The boiler room are moving on hence your chat numbers are moving towards the norm, SP should settle back in the 1p range until revenues become more certain. let it settle then add for the longer term if you want to.
Good luck
Getting close to my 1.5 buy back in price .
You seem to have a never ending money supply Laura..!! Your conviction must be strong because you’ve been buying at much higher prices.
£2000 more just now and aim to add £15k by Monday
Direct access to the funding will be a real boost for the company.
The "drip effect" will also be very beneficial.
I can see many doors now opening for the company leading to lucrative and frequent contracts.
I expect an exciting ride from this investment.
Acker
Yesterday Valirx put out a tweet saying "fantastic news" etc, however the tweet cam with no link to this news and with a few hashtags, no mention of Horizon.
so this morning, i sort clarification from Suzy Dilly, and she replied straight away that the tweet was about Horizon, and she would get her social media team to send out the news link etc.
You would have to expect that if its good news for VAL, this Horizon deal has to be good for PYC? Not only Vla and others to attempt to get funding for their companies, that trickle down affect should be good for PYC. PYC could also apply for funding for its own initiatives.
It's been a good few days here with some excellent progress being announced by PYC plus some top due diligence on where PYC is heading by many posters on this forum. However, I'm expecting PYC to achieve 20p a share in the next 12 - 18 months (at least) - which will still only be a Mcap of £27 Million. That's peanuts in this sector. That's when the big money will start to be made....
Good luck, Brighty
You'll be going TR1 soon if carry on buying L!